Baxter International Inc. and Claris Lifesciences Limited have agreed to divest two types of pharmaceutical products to settle Federal Trade Commission charges that Baxter’s proposed $625 million acquisition of Claris’ injectable drugs business is anticompetitive. According to a complaint filed by the FTC, the acquisition as proposed is likely to: reduce current competition in the […]